August 29, 2016:
Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers…
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
August 24, 2016:
Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.
August 17, 2016:
Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.
August 11, 2016:
Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Companys Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.
Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer
June 22, 2016:
Nymox Pharmaceutical Corporation announced today results from the Companys 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Companys lead drug fexapotide.
February 9, 2016:
Nymox Pharmaceutical Corporation today announced results from the completion of the Companys U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).
February 4, 2016:
Nymox Pharmaceutical Corporation announced today private placement equity investment of US$2.1 Million.
December 31, 2015:
Nymox Pharmaceutical Corporation is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements.
December 17, 2015:
Nymox Pharmaceutical Corporation is pleased to report an update on the Corporations business as of December 16, 2015.
October 29, 2015:
Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.